| abstract |
The proposed compounds, pharmaceutical compositions, including such compounds, as well as methods for their preparation and use. The compounds are N-aryldiazaspyrocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, as well as prodrugs and metabolites of such compounds. The aryl group may be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and / or prevent various conditions or disorders, especially such disorders, which are characterized by dysfunction of cholgenic neurotransmitters, including disorders of neuromodulation of neurotransmitter secretion, for example, dopamine release. Another example of disorders that can be treated and / or prevented is CNS disorders characterized by changes in the normal secretion of neurotransmitters. The compounds and compositions can also be used to relieve pain conditions. The proposed compounds are capable of (i) altering the number of nicotinic cholinergic receptors in a patient’s brain, (ii) exhibiting neuroprotective effects, and (iii) not using noticeable side effects when used in effective amounts (for example, such noticeable effects as a significant increase in blood pressure and heart cuts, significant adverse effects on the gastrointestinal tract and significant effects on skeletal muscle). The international search report was published on 2004.05.13. |